We are international
Donate
TEXT SIZE   
   back

Advocacy Update - October 2013
10.18.13
Header
  Donate Facebook Twitter Myeloma Minute  

IMF testifies in Wisconsin to Pass Oral Treatment Access Legislation

“On Wednesday, as I stepped into the Wisconsin State Capitol rotunda, I could feel the energy and hear the buzz of advocates from across Wisconsin gathered to attend the first committee hearing on the Cancer Treatment Fairness Act, SB 300,” Myeloma ACTION team leader Mary Polancih recalls. “And when we crowded into the hearing room, we surprised the Senate Insurance & Housing Committee who had to open an overflow room for advocates in support of the bill.” With standing room only, National State Affairs Consultant Zina Cary and IMF advocate Tom Chelius testified on the critical nature of the bill. Read More

Take Action on State Legislation

Health Reform and You Webinar: Navigating the Health Insurance Marketplaces

Please join us for the next in our series of webinars on the Affordable Care Act on Thursday, November 21 at 7 PM eastern/4 pm pacific. You will hear from experts who will discuss everything you need to know to apply for health insurance coverage through the new health insurance marketplaces plus questions that ALL myeloma patients should ask when searching for a new insurance plan. Click here to register today!

Resources

As the Bill Turns...Episode 6: Federal Addition

This summer, the Myeloma ACTION Team challenged themselves to meet with twenty federal legislators to ask for support of H.R. 1801, the Cancer Drug Coverage Parity Act. Halfway to our goal, we wanted to share with you our progress from accross the country. Read more

Take Action on Federal Legislation

The Federal Oral Parity Bill: HR 1801

The PACT Act: HR 4277

IMF Launches Two New Websites for PEAC and SPEAC

We are excited to announce the launch of two new websites. The Patients Equal Access Coalition (PEAC ) and State Patients Equal Access Coalition (SPEAC), both managed by the IMF, have revived their sites to include the most relevant and up-to-date information concerning Federal and State initiatives on patient access issues. Visit the PEAC site to follow the work we've been doing on The Cancer Drug Coverage Parity Act; write to Congress to ask for support; share your personal story; and much more. Tour the SPEAC site to learn about pending state legislation and states that have the laws in place, and how you can get involved. Please check out peac.myeloma.org and speac.myeloma.org for more information.

Multiple Myeloma Insurance Questionnaire

Questions for patients to consider when shopping for a new health insurance plan through a new health exchange

Click here for details

Update on The California Access to Cancer Treatment Act

On October 9, Governor Brown signed AB 219, the Access to Cancer Treatment Act into law. As you recall, the IMF along with partners NPAF and NAACP came out against this bill after damaging amendments were added in early September. We were disappointed with the final version of the legislation and will continue to work on improving access to treatment for Californians. Read our memo of opposition here

Myeloma ACTION Team
 
Advocates
Committed
To
Inspiring
Others
Nationwide

Check out the Advocate Blog
Advocacy Tip of the Month
 

** Be proactive in your health care coverage and make sure you have the most cost effective plan for you. Right now is the open enrollment period for Medicare and you can look into plans that might better suit your needs as a myeloma patient. Check out www.medicare.gov for more information. **

 
Star
 

 

 

 


 related videos
 related articles
Advocacy Update
...

Advocacy Update
...

Advocacy Update - Au...
Advocacy Upd...
Advocacy Update - Ju...
Advocacy Update - Ma...
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Fe...
Advocacy Update - Ja...
Advocacy Update - De...
Advocacy Update - No...
Advocacy Update - Oc...
Advocacy Update - Au...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ma...
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Fe...
Advocacy Update - Ja...
Advocacy Update - De...
Advocacy Update: Adv...
Advocacy Update - No...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Fe...
Advocacy Update - Ja...
Advocacy Update - De...
Advocacy Update - No...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update - Au...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ma...
Advocacy Update - Ap...
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Ma...
Advocacy Update - Fe...
Advocacy Update - Fe...
Advocacy Update - Ja...
Advocacy Update - Ja...
The IMF Invites advo...
Advocacy Update - De...
Advocacy Update - No...
Advocacy Update - No...
The Importance of Vo...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update - Se...
Advocacy Update - Au...
Advocacy Update - Au...
Advocacy Update - Au...
Letter from House to...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ma...
Myeloma Advocacy Upd...
Myeloma Advocacy Upd...
Advocacy Update - Ma...
Advocacy Update - Fe...
Myeloma Advocacy Upd...
Advocacy Update - Ja...
Advocacy Update - De...
Advocacy Update: Nov...
Advocacy Update - Se...
Advocacy Update - Se...
Advocacy Update - Au...
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
ASH 2014: Dr. Shaji ...
ASH 2014: Dr. Shaji ...
Audio Recording of C...
August 2013 Advocate...
Best of ASH 2014 - W...
Breaking News: Pomal...
FDA Recognition of E...
Freelite and Hevylit...
Health Reform and Yo...
Highlights from the ...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
IMF TV
IMWG 2014 Conference...
Infoline
International Myelom...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Living Well With Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma Minute Sept...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
News Briefing: The L...
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Gains Nation...
The IMF Spearheads N...
The Importance of Cl...
The IMWG Conference ...
The IMWG Conference ...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
Advocacy Update
October 2014
Advocacy Update
September 2014
Advocacy Update - August 2014
Advocacy Update - July 2014
Advocacy Update - June 2014
Advocacy Update - May 2014
Advocacy Update - April 2014
Advocacy Update - March 2014
Advocacy Update - February 2014
Advocacy Update - January 2014
Advocacy Update - December 2013
Advocacy Update - November 2013
Advocacy Update - October 2013
Advocacy Update - August 2013
Advocacy Update - July 2013
Advocacy Update - June 2013
Advocacy Update - May 2013
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - February 2013
Advocacy Update - January 2013
Advocacy Update - December 2012
Advocacy Update: Advocacy Training in Atlanta Inspires Patients to Take Action!
Advocacy Update - November 2012
Advocacy Update - October 2012
Advocacy Update - September 2012
Advocacy Update - July 2012
Advocacy Update - June 12, 2012
Advocacy Update - April 15, 2012
Advocacy Update - March 21, 2012
Advocacy Update - February 15, 2012
Advocacy Update - January 16, 2012
Advocacy Update - December 19, 2011
Advocacy Update - November 15, 2011
Advocacy Update - October 15, 2011
Advocacy Update - September 16, 2011
Advocacy Update - August 15, 2011
Advocacy Update - July 15, 2011
Advocacy Update - June 15, 2011
Advocacy Update - June 2011
Advocacy Update - June 2011
Advocacy Update - May 15, 2011
Advocacy Update - April 30, 2011
Advocacy Update - April 15, 2011
Advocacy Update - March 31, 2011
Advocacy Update - March 15, 2011
Advocacy Update - February 28, 2011
Advocacy Update - February 15, 2011
Advocacy Update - January 31, 2011
Advocacy Update - January 20, 2011
The IMF Invites advocates in Wisconsin to Attend the 2011 Wisconsin ‘Day at the Capitol’
Advocacy Update - December 15, 2010
Advocacy Update - November 30, 2010
Advocacy Update - November 15, 2010
The Importance of Voting on November 2nd
Advocacy Update - October 15, 2010
Advocacy Update - September 30, 2010
Advocacy Update - September 15, 2010
Advocacy Update - August 31, 2010
Advocacy Update - August 17, 2010
Advocacy Update - August 5, 2010
Letter from House to NCI - Improve Outcomes for the Deadliest Cancers
Advocacy Update - July 15, 2010
Advocacy Update - June 30, 2010
Advocacy Update - June 21, 2010
Advocacy Update - May 31, 2010
Myeloma Advocacy Update - May 3, 2010
Myeloma Advocacy Update - March 30, 2010
Advocacy Update - March 2, 2010
Advocacy Update - February 15, 2010
Myeloma Advocacy Update - January 31, 2010
Advocacy Update - January 15, 2010
Advocacy Update - December 17, 2009
Advocacy Update: November 5, 2009
Advocacy Update - September 15, 2009
Advocacy Update - September 1, 2009
Advocacy Update - August 3, 2009
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
ASH 2014: Dr. Shaji Kumar's Overview
ASH 2014: Dr. Shaji Kumar's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Best of ASH 2014 - What Patients Need to Know
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
Highlights from the 5th Annual IMWG Summit: Part 2
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
IMF TV
IMWG 2014 Conference Series Debate: Making Sense of Treatment
Infoline
International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Living Well With Myeloma:
Understanding the Immune System and Lab Values in Myeloma
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
September 18, 2014
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Gains National Recognition for Myeloma Awareness Month in 2014
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The IMWG Conference Series "Making Sense of Treatment"
Dec. 8, 2014
The IMWG Conference Series "Making Sense of Treatment"
June 11, 2014
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций


You might also be interested in:

Advocacy Update
October 2014

Advocacy Update
September 2014

Advocacy Update - August 2014

Advocacy Update - July 2014

Advocacy Update - June 2014

Advocacy Update - May 2014

Advocacy Update - April 2014

Advocacy Update - March 2014

Advocacy Update - February 2014

Advocacy Update - January 2014

Advocacy Update - December 2013

Advocacy Update - November 2013

Advocacy Update - October 2013

Advocacy Update - August 2013

Advocacy Update - July 2013

Advocacy Update - June 2013

Advocacy Update - May 2013

Advocacy Update - April 2013

Advocacy Update - March 2013

Advocacy Update - February 2013

Advocacy Update - January 2013

Advocacy Update - December 2012

Advocacy Update: Advocacy Training in Atlanta Inspires Patients to Take Action!

Advocacy Update - November 2012

Advocacy Update - October 2012

Advocacy Update - September 2012

Advocacy Update - July 2012

Advocacy Update - June 12, 2012

Advocacy Update - April 15, 2012

Advocacy Update - March 21, 2012

Advocacy Update - February 15, 2012

Advocacy Update - January 16, 2012

Advocacy Update - December 19, 2011

Advocacy Update - November 15, 2011

Advocacy Update - October 15, 2011

Advocacy Update - September 16, 2011

Advocacy Update - August 15, 2011

Advocacy Update - July 15, 2011

Advocacy Update - June 15, 2011

Advocacy Update - June 2011
Bart Barlogie, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkanas, USA

Advocacy Update - June 2011
Bart Barlogie, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkanas, USA

Advocacy Update - May 15, 2011

Advocacy Update - April 30, 2011

Advocacy Update - April 15, 2011

Advocacy Update - March 31, 2011

Advocacy Update - March 15, 2011

Advocacy Update - February 28, 2011
As you know, the Federal government is operating under a Continuing Resolution (CR), as Congress has not passed any of the appropriations bills for Fiscal Year (FY) 2011. The current CR expires on March 4. If Congress does not reach an agreement prior to that time, many functions of the Federal government would be curtailed.

Advocacy Update - February 15, 2011
The text of the House fiscal year 2011 Continuing Resolution was released last week and it provides cuts to the cancer research and control programs at the National Institutes of Health, Centers for Disease Control and Prevention, and the Food and Drug Administration.

Advocacy Update - January 31, 2011
President Obama outlined his priorities in his recent State of the Union address including a medical malpractice overhaul and eliminating new IRS tax reporting requirements. He also pledged his support of action to improve the health care overhaul law. However, he does not support full scale repeal of the Patient Protection and Affordable Care Act (PPACA).

Advocacy Update - January 20, 2011
The House voted to repeal 245-189 the Patient Protection and Affordable Care Act (ACA) on January 19. The symbolic vote was along party lines with only 3 Democrats [Representatives Dan Boren (D-OK), Mike Ross (D-AR), and Mike McIntyre (D-NC)] voting with the Republicans.

The IMF Invites advocates in Wisconsin to Attend the 2011 Wisconsin ‘Day at the Capitol’
Wednesday, March 2, 2011
10:00 a.m. – 4:30 p.m.

For more information and to sign up, please visit: ‘A Day at the Capitol’ Information and Registration Website

Voice your support for legislation that will help increase patient access to all chemotherapy treatments!

The IMF has joined the Wisconsin Coalition for Cancer Treatment Access (WCCTA) and is working with them to ensure equal access to chemotherapy treatments for patients in Wisconsin. Please visit www.thewccta.org for more information.

Advocacy Update - December 15, 2010
Below is a summary of some of the legislative issues that IMF has followed in the second session of the 111th Congress. As you can see, we were successful on many important issues such as ensuring access to clinical trials and declaring September Blood Cancer Awareness Month.

Advocacy Update - November 30, 2010
Issues Congress must finish before adjourning the 111th Congress include finalizing funding for the federal government and the expiring tax cuts.

Advocacy Update - November 15, 2010
The mid-term elections will create change in the Nation's capital in the 112th Congress. What do the election results mean for the myeloma community?

The Importance of Voting on November 2nd
Voting is important because our elected officials (at all levels) are supposed to work for us. Our legislators make the laws that we have to follow every day and that impact our lives from the moment we get up in the morning until we go to sleep at night.

Advocacy Update - October 15, 2010

On October 5th, the President signed the Improving Access to Clinical Trials Act into law.


Advocacy Update - September 30, 2010
The U.S. House of Representatives passed the Improving Access to Clinical Trials Act (HR 2866) on September 23rd. The legislation, which passed the Senate on August 5th, now goes to the White House where President Obama is expected to sign it.

Advocacy Update - September 15, 2010
One hundred cosponsors of H Res 1433 cleared the way for The House Energy and Commerce Committee to hold a hearing on this resolution, which encourages greater support for blood cancer research and education.

Advocacy Update - August 31, 2010
Representative Reichert Circulates "Dear Colleague" Letter to New NCI Director asking him to consider increasing the Institute's commitment to organ-specific research at the NCI through a targeted research program for the deadliest cancers.

Advocacy Update - August 17, 2010
Can You Spare 5 Minutes for Blood Cancer Awareness Month?

Advocacy Update - August 5, 2010
Cancer Research Receives Boost in House and Senate LHHS Appropriations Bills

Letter from House to NCI - Improve Outcomes for the Deadliest Cancers
Letter from Representative Dave Reichart to new NCI Director Varmus.

Advocacy Update - July 15, 2010
Increase of $214 million for FDA in House Appropriations Subcommittee Mark Up

Advocacy Update - June 30, 2010
Does Your Representative Support Blood Cancer Awareness Month? Resolution 1433 recognizes September 2010 as Blood Cancer Awareness Month. We need your help to secure 90 cosponsors before this bill will be considered by the House Energy and Commerce Committee.

Advocacy Update - June 21, 2010
Representatives Walther Jones (R-NC) and Betsy Markey (D-CO) recently introduced a resolution (H. Res.1433) designating September 2010 as Blood Cancer Awareness Month.

Advocacy Update - May 31, 2010
Have Questions About the Temporary High Risk Health Insurance Pool? The health reform law creates a temporary national high-risk pool that will be created to provide health coverage to people with pre-existing medical conditions who have been uninsured for six months.

Myeloma Advocacy Update - May 3, 2010
NIH Testifies About FY 2011 Research Budget and the ever-present scramble for money was a continuing theme.

Myeloma Advocacy Update - March 30, 2010
On Tuesday, March 23rd, the President signed into law the Patient Protection and Affordable Care Act which transforms significant portions of the health care environment and contains a number of reforms that will be extremely beneficial for myeloma patients.

Advocacy Update - March 2, 2010
President Unveils Health Reform Proposal and White House Hosts Health Reform Summit

Advocacy Update - February 15, 2010
President’s Budget Includes Funding Increases and Cuts to Blood Cancer Programs

Myeloma Advocacy Update - January 31, 2010
Progress in passing health care reform legislation has significantly slowed. Congressional leaders are currently determining how to pass this important legislation as well as what a final package might look like and what the timing might be.

Advocacy Update - January 15, 2010
Since the Senate passed the Patient Protection and Affordable Care Act (H.R. 3590), on December 24th, the House and Senate have been trying to work out the differences between the two bills. On January 13th, President Obama and top Congressional Democrats held a marathon negotiating session in an effort to thrash out agreements on health care reform.

Advocacy Update - December 17, 2009
A summary of some of the legislative issues that IMF has followed in the first session of the 111th Congress. As you can see, we were successful on many important issues such as increasing funding for cancer research in both the economic stimulus package as well as in fiscal year (FY) 2010 at the National Institutes of Health (NIH) and the National Cancer Institute (NCI). However, Congress still has unfinished business on health care reform legislation.

Advocacy Update: November 5, 2009
The House of Representatives released its updated version of the health care reform bill. H.R. 3962, the Affordable Health Care for America Act, is the merged versions of the health care bills passed out of the House Energy & Commerce, Ways & Means, and the Education & Labor Committees. HR 3962 would cover 96 percent of Americans, reduces the deficit and provides coverage for an additional 37 million Americans. It closes the drug benefit doughnut hole for seniors and sets a floor for Medicaid at 150 percent of federal poverty - about $33,075 for a family of four.

Advocacy Update - September 15, 2009
President Barack Obama’s address to Congress last week helped to move the Congress closer to passing comprehensive health insurance reform. In his speech, the President stated his case to Congress: health insurance reform must pass this year. He stressed that repeating history by doing nothing is not an option and laid out specific benchmarks for reform. He reminded Congress that effective health reform is essential to restoring the country’s long-term fiscal health and securing a stronger future for our children.

Advocacy Update - September 1, 2009
Congress returns to work on September 8th and the top priority will be passing heath care reform. Without Senator Ted Kennedy (D-MA), Congressional Democrats will need to figure out how to keep the debate on health care reform bipartisan which they view as key to passing reform. Over the August Congressional Recess period, many Congressional members hosted contentious town hall meetings with constituents on this very issue.

Advocacy Update - August 3, 2009
Both the House of Representatives and the Senate forged ahead on health care reform; however, neither the House nor the Senate were able to pass their respective versions of health care reform before adjourning for the August Congressional recess period which begins on August 3rd. Unfortunately, this delay means that Congress will miss the deadline set by the President earlier this year to enact health care reform.